Overview

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Quetiapine Fumarate